Design and interpretation of equivalence trials
- 1 April 2000
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 139 (4) , S171-S176
- https://doi.org/10.1016/s0002-8703(00)90067-x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial InfarctionCirculation, 1996
- More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial InfarctionCirculation, 1995
- The case for confidence intervals in controlled clinical trialsControlled Clinical Trials, 1994
- The glitter of the t tableThe Lancet, 1993
- A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.Journal of Clinical Oncology, 1992
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemiaBlood, 1991
- Guidelines for Statistical Reporting in Articles for Medical JournalsAnnals of Internal Medicine, 1988